Sputnik V | Second batch of Sputnik V vaccine to arrive in India tomorrow; Kejriwal writes to Dr Reddy’s for 67 lakh doses

Second batch of Sputnik V vaccine to arrive in India tomorrow; Kejriwal writes to Dr Reddy's for 67 lakh doses


‘Now we have requested for 67 lakh doses’&nbsp

Key Highlights

  • Russian Ambassador to India, Nikolay Kudashev expressed his happiness over the rollout of COVID-19 vaccine Sputnik V in India
  • Delhi govt authorities has written to Dr Reddy’s Laboratories for provide of round 67 lakh doses of Sputnik V vaccine
  • No response has come from their facet as but: Arvind Kejriwal

New Delhi: The second batch of the Sputnik V vaccine will arrive in India on Could 16.

The vaccine developed by Gamaleya Analysis Institute, a part of Russia’s Ministry of Well being, is being distributed in India by Dr Reddy’s Laboratories.

In the meantime, Delhi Chief Minister Arvind Kejriwal in the present day stated that his authorities has written to Dr Reddy’s Laboratories for the provision of round 67 lakh doses of Sputnik V.

Sputnik V is the primary foreign-made vaccine for use in India

This comes after Deputy Chief Minister Manish Sisodia earlier this week claimed that Covaxin producer Bharat Biotech has refused to offer further doses.

“Now we have requested for 67 lakh doses every of Covishield and Covaxin and have written to Dr Reddy’s who’re sellers of Sputnik in India for almost an identical quantity,” stated Kejriwal including that the response from Dr Reddy’s is awaited.

Sputnik V is the primary foreign-made vaccine for use in India and the retail worth of the vaccine is Rs 995.40 and the fee might come down as soon as native manufacturing begins.

The primary consignment from Russian Direct Funding Fund (RDIF) landed in India on Could 1.

Six Indian drug companies to fabricate Sputnik V vaccine in India

RDIF has tie-ups with six Indian drug companies to fabricate the vaccine in India.

Calling India a number one manufacturing hub for Sputnik V, RDIF has reached agreements with Indian pharmaceutical firms – Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, and Virchow Biotech – to provide the vaccine domestically with a goal of 850 million doses per yr.

In the meantime, India’s cumulative vaccination protection exceeds 18 crore on Saturday below Part-Three of the nationwide vaccination drive.

A complete of 18,04,57,579 vaccine doses have been administered by means of 26,02,435 periods, Union Well being Ministry’s provisional report until 7 a.m. on Saturday reveals, reported IANS including that these vaccine doses embody 96,27,650 Healthcare Staff (HCWs) who’ve taken the primary dose and 66,22,040 HCWs who’ve been administered the second dose.

Scroll to Top